Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:...in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either....a deleterious or suspected deleterious BRCA mutation...

Lynparza in combination with bevacizumab is indicated for the:...maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability...

Ovarian cancer/Fallopian Tube cancer/Primary Peritoneal cancer: NCCN Recommended Options for Maintenance After First-Line Chemotherapy:...BRCA1/2 mutated...Recommended Options...Bevacizumab + olaparib.

Eligible patients...high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer....median progression-free survival was 22.1 months with olaparib plus bevacizumab and 16.6 months with placebo plus bevacizumab (hazard ratio for disease progression or death, 0.59; 95% confidence interval [CI], 0.49 to 0.72; P<0.001)....In patients with advanced ovarian cancer receiving first-line standard therapy including bevacizumab, the addition of maintenance olaparib provided a significant progression-free survival benefit, which was substantial in patients with HRD-positive tumors, including those without a BRCA mutation.